Table 2.

The comparison of 24 months survival and cyclin D1 expression in selected groups of patients.

Survival	Positive Cyclin D1 expression n (%)	Negative Cyclin D1 expression n (%)	Chi2 Yatesa	p	Cox Mantel
All examinated patients with NSCLC
< 24 months	16 (41.03%)	4 (50%)	0.01	0.940	0.624
≥ 24 months	23 (58.97%)	4 (50%)
The patients with squamous cell carcinoma
< 24 months	8 (38.10%)	2 (66.67%)	0.10	0.754	0.234
≥ 24 months	13 (61.90%)	1 (33.33%)
The patients with adenocarcinoma
< 24 months	7 (58.33%)	1 (33.33%)	0.02	0.897	0.396
≥ 24 months	5 (41.67%)	2 (66.67%)
Stage II
< 24 months	4 (100%)	1 (25%)	2.13	0.144	0.076
≥ 24 months	0 (0%)	3 (75%)
Stage III
< 24 months	6 (42.86%)	1 (50%)	0.33	0.567	0.544
≥ 24 months	8 (57.14%)	1 (50%)
Stage IV
< 24 months	3 (75%)	2 (100%)	0.15	0.698	0.085
≥ 24 months	1 (25%)	0 (0%)